Trial record 11 of 34 for:    Open Studies | "Panic Disorder"

Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Inje University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Inje University
ClinicalTrials.gov Identifier:
NCT00492414
First received: June 26, 2007
Last updated: August 7, 2007
Last verified: March 2007
  Purpose

Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.


Condition Intervention Phase
Panic Disorder
Drug: Paroxetine CR
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research

Resource links provided by NLM:


Further study details as provided by Inje University:

  Eligibility

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. Male or female outpatients aged 20-50 years
  2. In female, is eligible to enter this study if she is if

    • Non-childbearing potential(note:women who are 6 months post-menopausal are not considered women of child-bearing potential)
    • child-bearing potential, has a negative urine dipstick pregnancy test, and is practicing a clinically acceptable method of contraception such as oral contraception, surgical sterilization, I.U.D.,systemic contraception, or double barrier contraception(any two of diaphragm/spermicidal foar/condom)
  3. Subject currently meets the diagnosis for PD according to korean version of Anxiety Disorder Interview Schedule for DSM-IV(ADIS-IV) through a comprehensive psychiatric evaluation and not being treated currently.
  4. Subject must have the ability to comprehend the key components of the consent form and provide informed consent.

Exclusion Criteria:

  1. Subject who has a history of any other major medical or psychiatric illnesses except PD or PD with major depressive disorder.
  2. Subject who retired or left his job or who plan to retire within two years.
  3. is a current homicidal or suicidal risk in the investigator's judgement.
  4. is currently pregnant, lactating or planning to become pregnant within the next 3 months
  5. is currently participating in any other clinical trial or taking any non-approved or experimental medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492414

Contacts
Contact: Eun-Joo Jung +82-2-2270-0940 menfipro@naver.com

Locations
Korea, Republic of
Seoul Paik Hospital, Inje University Recruiting
Seoul, Korea, Republic of
Contact: Eun-Joo Jung    +82-2-2270-0940    menfipro@naver.com   
Sponsors and Collaborators
Inje University
GlaxoSmithKline
Investigators
Principal Investigator: Jong-Min Woo, Master Seoul Paik Hospital, Inje University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00492414     History of Changes
Other Study ID Numbers: COL110010
Study First Received: June 26, 2007
Last Updated: August 7, 2007
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Inje University:
Panic disorder (PD)

Additional relevant MeSH terms:
Panic Disorder
Anxiety Disorders
Mental Disorders
Paroxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 26, 2014